Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. [2008.09]
A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. [2008.09]
Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels. [2008.08]
Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma. [2008.05]
The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. [2008.04]
Comparison of 30% salicylic acid with Jessner's solution for superficial chemical peeling in epidermal melasma. [2008.04]
An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. [2008.04]
Skin-lightening effects of a new face care product in patients with melasma. [2008.03]
Efficacy and safety of cryotherapy vs. trichloroacetic acid in the treatment of solar lentigo. [2008.03]
Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature. [2008.02]
Long-pulse pulsed dye laser delivered with compression for treatment of facial lentigines. [2007.08]
Case reports: clearance of lentigines in Japanese men with the long-pulsed alexandrite laser. [2007.06]
Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial. [2007.05]
Treatment of pigmented lesions of neurofibromatosis 1 with intense pulsed-radio frequency in combination with topical application of vitamin D3 ointment. [2007.04]
A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. [2007.03]
Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma. [2007.02]
Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. [2007.01]
A comparative study of focal medium-depth chemical peel versus cryosurgery for the treatment of solar lentigo. [2007.01]
Phenol-castor oil: modified peel for dermal melasma. [2006.05]
Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. [2006.05]
A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: a randomized, physician-blinded, split-face comparative trial. [2006.05]
Sun protection strength of a hydroquinone 4%/retinol 0.3% preparation containing sunscreens. [2006.04]
Repeated treatment protocols for melasma and acquired dermal melanocytosis. [2006.03]
Community-based trial of a triple-combination agent for the treatment of facial melasma. [2006.03]
Treatment of hyperpigmentation-melasma with photodynamic therapy. [2006.02]
Q-switched ruby versus long-pulsed dye laser delivered with compression for treatment of facial lentigines in Asians. [2006.02]
Laser therapy for solar lentigines: review of the literature and case report. [2006]
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. [2005.09]
DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. [2005.08]
Novel approach to the treatment of hyperpigmented photodamaged skin: 4% hydroquinone/0.3% retinol versus tretinoin 0.05% emollient cream. [2005.07]
Utilizing fractional resurfacing in the treatment of therapy-resistant melasma. [2005.03]
Corrective cosmetics are effective for women with facial pigmentary disorders. [2005.03]
Lactic acid as a new therapeutic peeling agent in melasma. [2005.02]
Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. [2005.01]
A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. [2004.12]
Oral intake of proanthocyanidin-rich extract from grape seeds improves chloasma. [2004.11]
Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. [2004.11]
The use of lasers and intense pulsed light sources for the treatment of pigmentary lesions. [2004.10]
Safety and efficacy of combined use of 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% solution and sunscreen in solar lentigines. [2004.10]
Utilizing combination therapy to optimize melasma outcomes. [2004.09]
Intense pulsed light for the treatment of refractory melasma in Asian persons. [2004.09]
A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. [2004.08]
Improved quality of life with effective treatment of facial melasma: the pigment trial. [2004.07]
Tretinoin peels versus glycolic acid peels in the treatment of Melasma in dark-skinned patients. [2004.05]
Focal trichloroacetic acid peel method for benign pigmented lesions in dark-skinned patients. [2004.04]
Rationale for the use of topical corticosteroids in melasma. [2004.03]
Melasma: a review. [2004.03]
Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma. [2004.03]
The use of lasers and intense pulsed light sources for the treatment of acquired pigmentary lesions in Asians. [2003.12]
1 2 Next >>
